



### **Follicular Lymphoma Suggested Readings**

Amengual JE. Can we use epigenetics to prime chemoresistant lymphomas? *Hematology Am Soc Hematol Educ Program*. 2020;2020:85-94. doi:10.1182/hematology.2020000092

Ardeshtna KM et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. *Lancet*. 2003;362:516-522. doi:10.1016/s0140-6736(03)14110-4

Brice P et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. *J Clin Oncol*. 1997;15:1110-1117. doi:10.1200/JCO.1997.15.3.1110

Busch C et al. Epigenetic activities of flavonoids in the prevention and treatment of cancer. *Clin Epigenetics*. 2015;7:64. doi:10.1186/s13148-015-0095-z

Casulo C et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. *J Clin Oncol*. 2015;33:2516-2522. doi:10.1200/JCO.2014.59.7534

Casulo C, Barr PM. How I treat early-relapsing follicular lymphoma. *Blood*. 2019;133:1540-1547. doi:10.1182/blood-2018-08-822148

Casulo C et al. Autologous transplantation in follicular lymphoma with early therapy failure: a National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. *Biol Blood Marrow Transplant*. 2018;24:1163-1171. doi:10.1016/j.bbmt.2017.12.771

Centers for Disease Control and Prevention. Lymphoma. Accessed September 16, 2021. <https://www.cdc.gov/cancer/lymphoma/index.htm>

Cortés JR, Palomero T. The curious origins of angioimmunoblastic T-cell lymphoma. *Curr Opin Hematol*. 2016;23:434-443. doi:10.1097/MOH.0000000000000261

Dreyling M et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. *J Clin Oncol*. 2017;35:3898-3905. doi:10.1200/JCO.2017.75.4648

Evens AM et al. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. *Cancer*. 2013;119:3662-3671. doi:10.1002/cncr.28243

Gopal AJ et al. PI3K $\delta$  inhibition by idelalisib in patients with relapsed indolent lymphoma. *N Engl J Med*. 2014;370:1008-1018. doi:10.1056/NEJMoa1314583

Italiano A et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. *Lancet Oncol.* 2018;19:649-659. doi:10.1016/S1470-2045(18)30145-1

Leonard JP et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. *J Clin Oncol.* 2019;37:1188-1199. doi:10.1200/JCO.19.00010

Leukemia and Lymphoma Society. NHL subtypes. Accessed September 16, 2021. <https://www.lls.org/lymphoma/non-hodgkin-lymphoma/diagnosis/nhl-subtypes>

Leukemia and Lymphoma Society. Treatment for indolent NHL subtypes. Accessed September 16, 2021. <https://www.lls.org/lymphoma/non-hodgkin-lymphoma/treatment/treatment-for-indolent-nhl-subtypes>

Lymphoma Research Foundation. Understanding follicular lymphoma: relapsed/refractory. Accessed May 10, 2021. [https://lymphoma.org/wp-content/uploads/2020/09/LRF\\_Factsheet\\_Follicular-Lymphoma-Relapsed\\_Refractory\\_090920.pdf](https://lymphoma.org/wp-content/uploads/2020/09/LRF_Factsheet_Follicular-Lymphoma-Relapsed_Refractory_090920.pdf)

Morschhauser F et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. *Lancet Oncol.* 2020;21:1433-1442. doi:10.1016/S1470-2045(20)30441-1

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. B-cell lymphomas. Version 4.2021. May 5, 2021. Accessed September 16, 2021. [https://www.nccn.org/professionals/physician\\_gls/pdf/b-cell.pdf](https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf)

National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Patients. Follicular lymphoma: non-Hodgkin's lymphoma series. 2019. Accessed September 16, 2021. <https://www.nccn.org/patients/guidelines/content/PDF/nhl-follicular-patient.pdf>

National Institutes of Health. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: NHL — follicular lymphoma. Accessed May 10, 2021. <https://seer.cancer.gov/statfacts/html/follicular.html>

Palomero T et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. *Nat Genet.* 2014;46:166-170. doi:10.1038/ng.2873

Pasqualucci L et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. *Nature.* 2011;471:189-195. doi:10.1038/nature09730

Ribrag V et al. Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study. *Haematologica.* 2017;102:903-909. doi:10.3324/haematol.2016.154377

Rohatiner AZ et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. *J Clin Oncol.* 2007;25:2554-2559. doi:10.1200/JCO.2006.09.8327

Schmitz R et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. *N Engl J Med.* 2018;378:1396-1407. doi:10.1056/NEJMoa1801445

Sehn LH et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. *Lancet Oncol.* 2016;17:1081-1093. doi:10.1016/S1470-2045(16)30097-3

Sermer D et al. Emerging epigenetic-modulating therapies in lymphoma. *Nat Rev Clin Oncol.* 2019;16:494-507. doi:10.1038/s41571-019-0190-8